1 / 21

Global impact of medicine shortages

Global impact of medicine shortages. Lisa Hedman World Health Organization Department of Essential Medicines and Health Products Toronto, Canada 20-21 June 2013 Photos courtesy of Lisa Hedman unless otherwise noted. Outline: Vulnerabilities in low- and middle-income countries

jewell
Télécharger la présentation

Global impact of medicine shortages

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Global impact of medicine shortages Lisa Hedman World Health Organization Department of Essential Medicines and Health Products Toronto, Canada 20-21 June 2013 Photos courtesy of Lisa Hedman unless otherwise noted.

  2. Outline: • Vulnerabilities in low- and middle-income countries • Case study: anti-tuberculosis medicines • Financing • Trade trends in BRICS countries • Unanswered issues

  3. Shortage of essential medicines is a global problem…and there is insufficient information to determine the magnitude and specifics characteristics of the problem Photo: Dr Charles Senessie, Swissmedic Bulletin of the World Health Organization 2012;90:158-158A. doi: 10.2471/BLT.11.101303

  4. Access to public sector medicines Policy environment Market environment

  5. Vulnerabilities in low- and middle-income countries

  6. Case study: anti-tuberculosis medicines WHO REPORT 2011 – GLOBAL TUBERCULOSIS CONTROL

  7. Case study: anti-TB medicines and policy change Scale of current products is different and too complex to use within treatment guidelines

  8. Case study: anti-TB medicines financing

  9. Case study: anti-TB medicines demand Demand estimated to drop below sustainable production levels when donor funding in India expires Cycloserine Slide detail excepted from Clinton Health Access Initiative data, 2012

  10. Case study: anti-TB medicines quality study Failure rate No sample suspected to be of spurious, falsely-labelled, falsified or counterfeit product

  11. Higher costs as a cause • The 17% of the world's population that live in low income countries accounted for only 1% of global pharmaceutical expenditure. • Relative to GDP, low income countries spent more than 30% of total health budgets on medicines, compared with 17% in high income countries. Source: The World Medicines Situation, 2011.

  12. Higher costs as a cause The World Medicine Situation 2011, Cameron et al, WHO

  13. Higher costs as a cause • Public sector prices paid for the lowest-priced generic medicines, range from 1.9 times to 3.7 times the international reference price (IRP) and from 5.3 times to 20.5 times for originator brands. • Private sector prices of originator brand medicines were at least 10 times higher than the corresponding international reference prices, and were as much as 20 and 30 times higher in Africa. The World Medicine Situation 2011, Cameron et al, WHO

  14. Example: Cost of Ciprofloxacin www.the.lancet.com, December 1, 2008, Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis; Cameron et al

  15. Example: Cost of Ciprofloxacin Median price ratios of public sector procurement prices for lowest-cost generics 4.32 2.55 www.the.lancet.com, December 1, 2008, Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary, analysis; Cameron et al

  16. Example: Availability of Cirpofloxacin Average country-level mean percentage of availability by WHO region 49% 24% www.the.lancet.com, December 1, 2008, Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary, analysis; Cameron et al

  17. Making the cost-benefit case • Higher costs can be measured • Challenges: lack of research and research approaches to determine the contribution of stock outs to the cost and burdens of: • Antimicrobial resistance (where alternative treatments can increase costs by 10-fold) • Irrational use • Contribution to increased mortality and morbidity

  18. Making the cost-benefit case: Supply Chain Costs • It is clear that additional investment would improve stock outs caused by national or local supply chain failures • Challenge: looking at the inverse, we do not know how much global shortages cost supply chains annually • Challenge: stock out prevalence reports vary widely, but what is the cost in terms of under-treatment?

  19. Are the BRICS making a difference? Unpublished WHO report: Pharmaceutical Trade Expenditures in BRICS Countries, based on data from WTO 2012

  20. What is missing? • Quantification of the global problem • Evaluation of the effectiveness of reporting systems (e.g., SMS for life et al) • Evaluation of the effectiveness of legislation and financing in preventing stock outs • Agreed approaches to quantify costs and impact on disease burden e.g., antimicrobial resistance • Criteria for escalating problems • Logical framework for managing shortages

  21. Thank you to all Photo: Dr Charles Senessie, SwissmedIc

More Related